Inhibition of hexonate dehydrogenase and aldose reductase from bovine retina by sorbinil, statil, M79175 and valproate - PubMed (original) (raw)
Inhibition of hexonate dehydrogenase and aldose reductase from bovine retina by sorbinil, statil, M79175 and valproate
R Poulsom. Biochem Pharmacol. 1986.
Abstract
Aldose reductase inhibitors (A.R.I.s), developed as potentially therapeutic agents for the treatment of complications of long-term diabetes, were found to be potent inhibitors of aldose reductase (ALR2) partially purified from bovine retina (IC50 values: Statil 0.89 microM, Sorbinil 2 microM, M79175 greater than 1 microM). These compounds varied, however, in their ability to inhibit hexonate dehydrogenase (ALR1), a closely related enzyme isolated from the same source (IC50 values: Statil greater than 1 microM, Sorbinil 3.9 microM, M79175 0.18 microM). Statil and Sorbinil were active against ALR2 at very low concentrations (approx. 5% inhibition at 100 pM), but did not inhibit ALR1 at less than or equal to 10 nM. In contrast, M79175 (structurally very similar to Sorbinil) and M7HEQ (a flavonoid) were preferential inhibitors of ALR1. Valproate, a compound of value in the treatment of epilepsies, was a poor inhibitor of ALR2 (18% at 1 mM). Furthermore, valproate was found to be a relatively poor inhibitor of ALR1, particularly in comparison with M79175.
Similar articles
- Inhibition of aldose reductase from human retina.
Poulsom R. Poulsom R. Curr Eye Res. 1987 Mar;6(3):427-32. doi: 10.3109/02713688709025198. Curr Eye Res. 1987. PMID: 3107906 - Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil.
O'Brien MM, Schofield PJ, Edwards MR. O'Brien MM, et al. J Neurochem. 1982 Sep;39(3):810-4. doi: 10.1111/j.1471-4159.1982.tb07964.x. J Neurochem. 1982. PMID: 6808090 - Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors.
Bhatnagar A, Liu SQ, Das B, Ansari NH, Srivastava SK. Bhatnagar A, et al. Biochem Pharmacol. 1990 Mar 15;39(6):1115-24. doi: 10.1016/0006-2952(90)90292-s. Biochem Pharmacol. 1990. PMID: 2157439 - Aldose reductase inhibitors and late complications of diabetes.
Benfield P. Benfield P. Drugs. 1986;32 Suppl 2:43-55. doi: 10.2165/00003495-198600322-00010. Drugs. 1986. PMID: 3098544 Review. - Medical therapy in the prevention of cataract.
Brown NA, Bron AJ. Brown NA, et al. Trans Ophthalmol Soc U K (1962). 1985;104 ( Pt 7):748-54. Trans Ophthalmol Soc U K (1962). 1985. PMID: 3938085 Review.
Cited by
- Inhibition of aldose reductase by dihydroflavonols in Engelhardtia chrysolepis and effects on other enzymes.
Haraguchi H, Ohmi I, Masuda H, Tamura Y, Mizutani K, Tanaka O, Chou WH. Haraguchi H, et al. Experientia. 1996 Jun 15;52(6):564-7. doi: 10.1007/BF01969729. Experientia. 1996. PMID: 8698090 - Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens.
Lee AY, Chung SK, Chung SS. Lee AY, et al. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2780-4. doi: 10.1073/pnas.92.7.2780. Proc Natl Acad Sci U S A. 1995. PMID: 7708723 Free PMC article. - An ABA and GA modulated gene expressed in the barley embryo encodes an aldose reductase related protein.
Bartels D, Engelhardt K, Roncarati R, Schneider K, Rotter M, Salamini F. Bartels D, et al. EMBO J. 1991 May;10(5):1037-43. doi: 10.1002/j.1460-2075.1991.tb08042.x. EMBO J. 1991. PMID: 1827067 Free PMC article. - Pharmacological treatment strategies in age-related cataracts.
Harding JJ. Harding JJ. Drugs Aging. 1992 Jul-Aug;2(4):287-300. doi: 10.2165/00002512-199202040-00003. Drugs Aging. 1992. PMID: 1504443 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials